As we have said before, FDA rulings can make or break the biotech sector, and short sellers and mega-bulls often go to war against each other in these companies. After all, if a single failed clinical trial can mean disaster for a stock, then some short sellers can argue for a stock implosion down the road.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The November 15 short interest data have been compared with the previous report, and short interest increased in most of the selected stocks.
Best Biotech Stocks To Invest In Right Now: BioMarin Pharmaceutical Inc.(BMRN)
Advisors' Opinion:- [By Chris Lange]BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is expected to report its most recent quarterly results on February 22. The consensus estimates from Thomson Reuters are calling for a net loss of $0.24 per share on $357.49 million in revenue. The same period of last year had a net loss of $0.53 per share and $300.09 million in revenue. Shares of BioMarin were last seen at $84.98, with a consensus price target of $110.32 and a 52-week range of $78.50 to $100.51.
- [By George Budwell, Rich Smith, and Matthew DiLallo]With this question in mind, we asked three of our contributors which stocks they recommend to buy and hold for the next 20 years. They suggested聽BioMarin Pharmaceutical (NASDAQ:BMRN), Enterprise Products Partners (NYSE:EPD), and聽Lockheed Martin (NYSE:LMT). Below, they discuss why they chose these particular stocks, and why investors with a long-term outlook may want to consider adding them to their portfolios right now.聽
- [By Chris Lange]Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is breaking out from a bullish continuation pattern after completing a 2-year+ consolidation bottom. Upside is seen to the $200 area. Celgene Corp. (NASDAQ: CELG), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), and Incyte Corp. (NASDAQ: INCY) have weaker technical patterns and may have further downside risks. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is forming a potential bearish top – a move below $77.98 would open $71 to the $60 area.
- [By Keith Speights]You might not have heard too much about Akebia Therapeutics (NASDAQ:AKBA), BioMarin Pharmaceutical (NASDAQ:BMRN), and Idera Pharmaceuticals (NASDAQ:IDRA). These are three biotech stocks that you could be overlooking -- but deserve your attention. Here's why.
Best Biotech Stocks To Invest In Right Now: Williams Partners L.P.(WPZ)
Advisors' Opinion:- [By Ben Levisohn]In a release after the close on Monday, Williams聽 and Williams Partners (WPZ) made several announcements, including: 1) outlining management鈥檚 plan to financially reposition and simplify the franchise鈥檚 GP/LP structure in an ~$11.4 billion transaction (not subject to any additional approvals), 2) adjustments to Williams and Williams Partners’ dividend and distribution payouts, 3) initiating a ~$2+ billion William equity raise to fund a further Williams investment in Williams Partners, 4) noted other potential upcoming changes, including the sale of ~$2 billion in non-core assets in 2017, and 5) provided several forms of updated 2017 guidance…
Best Biotech Stocks To Invest In Right Now: Microbot Medical Inc. (MBOT)
Advisors' Opinion:- [By Lisa Levin]Microbot Medical Inc (NASDAQ: MBOT) shares shot up 51 percent to $7.76 after reporting a significant technology patent allowance in the U.S. The patent allowance covers a device for the prevention of shunt stenosis.
- [By Lisa Levin]Shares of Microbot Medical Inc (NASDAQ: MBOT) got a boost, shooting up 15 percent to $8.77 after the company reported a 700,000 share direct offering for $3.5 million.
- [By Lisa Levin]Microbot Medical Inc (NASDAQ: MBOT) shares dropped 34 percent to $2.50. Microbot Medical reported a $10 million registered direct offering
Shares of NewLink Genetics Corp (NASDAQ: NLNK) were down 12 percent to $11.13 after the company reported that indoximod + PROVENGE resulted in statistically significant improvement in rPFS for patients with mCRPC in Phase 2 trial.
